Objectives/Hypothesis: Determine if oral treatment with a vasoconstrictor decreases the blood to middle ear exchange rate of the perfusion-limited gas, nitrous oxide (N 2 O).
INTRODUCTION
Middle ear (ME) pressure regulation (MEPR) is a homeostatic mechanism that maintains the ME-ambient pressure gradient within a narrow, zero-centered range that maximizes hearing and preserves ME health. 1 Hearing acuity is diminished as the absolute value of that gradient increases, and because the ME mucosal tissue pressure tracks local ambient pressure, large negative ME-ambient pressure gradients cause vascular disruption with leakage, mucosal inflammation, and fluid accumulation within the normally gas-filled ME, 2,3 a pathology not different from the clinical expression of otitis media with effusion (OME). 4 Thus, the risk for certain types of hearing loss and ME pathologies is indirectly related to MEPR efficiency. 1 The ME is usually a closed, relatively fixed-volume, temperature-stable, gas pocket. ME pressure is governed by the ideal gas law, P ME 5 RT ME (V ME ) 21 R s n ME s , and the rate of pressure change by the time-derivate of that equation, dP ME /dt5RT ME (V ME ) 21 R s dn ME s /dt, where P ME , T ME , and V ME are the ME pressure, temperature, and volume; R is a gas constant; n ME s is species moles, t is time, R s indicates summing over all represented species; and d denotes change. 1 Physiologically, ME pressure is changed by processes that change its species moles and, specifically, by passive gas transfers between the ME and adjacent compartments. 2 The ME simultaneously exchanges gas species with its local blood by diffusion across the ME mucosa (trans-MEM exchange), the ambient environment by diffusion across the tympanic membrane (trans-TM exchange), and the cochlear fluids by diffusion across the round window membrane (trans-RWM exchange). 2 The rates for these exchanges are given by Fick's law of diffusion, Q barrier s 5 CK barrier s DP barrier s , where Q barrier s is transbarrier volume gas flow, C is a moles-to-volume scaling constant, K barrier s is the species conductance for the barrier, and DP barrier s is the transbarrier species pressure gradient. Measurement shows that the trans-TM and trans-RWM species conductances are negligibly small compared to the respective trans-MEM conductances. 5, 6 Moreover, the only physiologically extant species gradient to drive trans-MEM gas exchange is the ME-blood N 2 gradient of approximately 600 daPa, because the ME-blood gradients for the other represented species, O 2 , CO 2 , and H 2 O, are well buffered at close to 0 daPa. 7, 8 Therefore, of the ME exchange pathways, only trans-MEM N 2 exchange satisfies the conditions for intercompartment gas exchange prescribed by Fick's diffusion equation, and the net direction, magnitude, and rate of pressure change for the closed ME under physiologic conditions are solely determined by the trans-MEM N 2 conductance and pressure gradient. For N 2 and other inert gases (e.g., N 2 O), the trans-MEM exchange rate is perfusion limited [9] [10] [11] [12] such that species conductance is proportional to the volume blood-flow rate per tissue volume (i.e., the perfusion rate), Q blood , and species solubility in the mucosa, S Consequently, the equilibrium pressure for a closed ME is equal to the ambient pressure minus the ME blood N 2 gradient (P ambient 2600 daPa), and the rate of ME pressure decrease to equilibrium is equal to the product of a scaling constant, the extant ME blood N 2 gradient, the mucosal perfusion rate and the trans-MEM N 2 conductance.
1 Therefore, the rate, but not the magnitude, of pressure change for a closed ME can be modulated by effecting changes in the mucosal blood perfusion rate. 13, 14 Periodic and transient, muscle-assisted eustachian tube (ET) openings establish a gas phase communication between the ME and nasopharynx (NP). Non-zero ME-NP (= ME-ambient) pressure gradients at the time of ET openings drive a bolus gas flow between the compartments according to the Hagen-Poiseuille equation, Q ET g 5 ET g DP C1-C2 g , which relates the trans-ET volume gas-flow rate, Q ET g , to the product of the trans-ET gas conductance, ' c g , and pressure gradient, DP ET g . These gas flows quickly change ME but not ambient pressure, and thereby decrease the preopening absolute value of the ME-ambient pressure-gradient. The efficiency of this ET pressure-equilibrating function can be expressed as the fractional ME-ambient pressure-gradient equilibrated per swallow (FGE), which is proportional to trans-ET gas conductance and ET opening duration, but independent of pressure gradient. 15 From these considerations, MEPR represents a time-limited balance in the ME volume gas influx (V iME g ) associated with ET openings and the volume-N 2 efflux (V eME N2 ) attributable to gradient-driven N 2 transfer from the ME to local blood. 1 For periods of stable ambient pressure, MEPR efficiency is directly related to the V iME g /V eME N2 ratio. Experiments show that disrupting that ME gas balance by decreasing ET efficiency (i.e., lowering V iME g ), 3, 16, 17 increasing ME to blood volume gas transfer (i.e., raising V eME g ), 18 or both causes ME pressure-dysregulation (MEPD) expressed as the sequential development of negative ME-ambient pressure-gradients, conductive hearing loss, and at a ME-ambient pressure-gradient of about 2250 daPa, ME mucosal inflammation, and OME. 17, 18 In persons with MEPD not caused by conditions that abolish trans-ET gas exchange (i.e., V iME g 5 0), the risk for these pathologies can be lessened by interventions that increase the V iME g /V eME N2 ratio. To that end, one relatively simple strategy is to effect a decrease in ME gas efflux by pharmacologically lowering the ME mucosal perfusion rate. This would effectively decrease the requisite volume gas influx (i.e., the frequency of ET openings and constitutive FGE) needed to stabilize the ME-ambient pressure-gradient at near 0 daPa (i.e., establish a V iME g /V eME N2 ratio of 1). Here, the feasibility of that strategy is explored by creating a significant trans-MEM inert gas pressure gradient and determining the effect, if any, of a vasoconstrictive drug on the rate of ME pressure change. The hypothesis tested is that the rate of ME pressure increase in response to a positive trans-MEM blood-ME N 2 O pressure gradient is reduced by treatment with pseudoephedrine hydrochloride (HCL) (PDE). 19 
MATERIALS AND METHODS

Study Population
The protocol was approved by the institutional review board at the University of Pittsburgh. Healthy adults, recruited by advertisement, presented to the laboratory and provided informed consent for study participation. Consented subjects provided medical and surgical histories and a comprehensive history for ME diseases, comorbidities, and predisposing conditions. They had an ear, nose, and throat (ENT) examination with bilateral tympanometry (Titan, Eden Prairie, MN), and women had a urine pregnancy test (Consult Diagnostics hCG Dipstick, Jacksonville, FL). Exclusion criteria consisted of pregnant women; persons with lactose intolerance, past adverse reaction to breathing gas mixtures containing N 2 O, or chronic illness; those who had taken prescription medication within the previous month (with the exception of birth control) or oral/ nasal decongestants within the 2 weeks before either test session; and those with extant unilateral or bilateral OME, low tympanic membrane compliance, or symptoms/signs of extant nasopharyngeal inflammation. The target population was 20 otherwise healthy adults, 10 with and 10 without past ME disease.
Protocol
The design was a randomized, double-blind, placebo-controlled, cross-over study requiring that participants complete paired N 2 O breathing sessions at a minimum 1-week interval. At each session, the subject reported to the research clinic, provided an interval history for medication use, ME disease, and upper respiratory diseases; had a brief ENT examination to verify continued eligibility; was pretreated with a doubleblinded, oral medication (identical appearing capsules containing either 60 mg of immediate-release PDE or lactose); and was then escorted to the dental clinic. There, the subject was seated in a reclined examination chair and fitted with the finger probe of a pulse oximeter (Masimo RDS1; Masimo Corp., Irvine, CA), the cuff of an automated blood pressure monitor (Critikon Dynamap 1846SX; Critikon Inc., Tampa, FL), and an appropriately sized Rudolph nasal and mouth breathing silicone face mask (Model 8900; Hans Rudolph, Inc., Shawnee, KS) with a two-way nonrebreathing valve. The delivery system supplying the mask was configured such that three gas sources could be placed online: room-air, a N 2 0 gas mixture (50% O 2 , 50% N 2 0), or 100% O 2 .
The experiment was begun 1 to 1.5 hours after dosing and consisted of a 20-minute acclimation period (period 1, room-air breathing), a 20-minute experimental period (period 2, gas-mixture breathing), and a 10-minute recovery period (period 3, 100% O 2 ). Throughout, bilateral ME pressures were recorded by tympanometry at 1-minute intervals, blood O 2 saturation and heart rate were monitored continuously and recorded every 5 minutes, and blood pressure was measured and recorded every 5 minutes. At the end of period 3, the subject was observed for 20 minutes, given a brief physical examination, and was free to leave the clinic when recovered from breathing the N 2 O gas mixture. At least 1 week later, these procedures were repeated, and the subject was dosed with the crossover capsule.
Pharmacology
PDE is a member of the phenethylamine and amphetamine chemical classes, with direct and indirect sympathomimetic actions. 20 Peak plasma concentrations are achieved between 1 and 2 hours, 21, 22 peak salivary concentrations between 2 and 4 hours, 23 and vasoconstrictive effects from 30 minutes to 4 hours after a single oral dose of 60-mg immediaterelease PDE.
19 N 2 O is a colorless and odorless gas that is highly insoluble in blood and other tissues. On breathing, N 2 O substitutes for N 2 , rapidly achieves blood alveolar equilibrium pressure, 24 and exhibits a perfusion-limited transmucosal exchange rate. 25 
Data Analysis
A randomization code was submitted to a pharmacist who prepared the 2 treatments as identical looking capsules supplied to the investigators in sealed bottles labeled by session and subject number. Personnel were blinded to the code until all recordings were double entered into a computer data file, reconciled, and locked to change.
For each session, the average blood O 2 saturation, heart rate, and systolic and diastolic blood pressures were calculated for periods 1 and 2, and the rate of increase in ME pressure was calculated for period 2. 25, 26 There, ME pressure-time functions were analyzed independently by two blinded investigators to calculate the slope of a linear segment representative of the change in ME pressure per change in time (dP ME /dt) during the last 15 minutes of period 2. Paired slope estimates were compared, discrepancies reconciled, and the average slopes used in the analysis.
The effects of group, treatment, period, and the treatment by group interaction on blood O 2 saturation, heart rate, and systolic and diastolic blood pressure, and the effects of treatment, group, ear (right/left), and the treatment by group interaction on the ME pressure-time slope were evaluated for significance using repeated measures analysis of variance (ANOVA) (NCSS 2007 statistical package, Kaysville, UT).
RESULTS
Twenty-six subjects were screened, three disqualified, and 23 enrolled. Twenty subjects (average age 5 26.7 6 8.8 years; 11 males; 13 white, six black, and one mixed race) completed the two test sessions. For group 1, six of the 10 subjects reported repeated episodes of ME effusion, eight reported three or more episodes of earache treated with antibiotics, and eight reported ventilation tube insertion(s) during childhood. Most (8/10) had outgrown their disease by late childhood, but one had ear problems into adolescence (13 years) and one (white female, aged 30.1 years) reported episodes of OME continuing into adulthood. No group 2 subject reported past OME or other ME diseases. Four subjects in each group had nasal allergy, none had asthma, and one in group-1 had gastroesophageal reflux disease.
There was a significant difference among individuals in all four vital signs measures (P <.001) and a significant but clinically irrelevant effect of group on systolic blood pressure (group 1 5 116 vs. group 2 5 107 mm Hg; P 5.040) and heart rate (group 1 5 68.5 vs. group-2 5 60.6 bpm; P 5.047), of period on O 2 saturation (period 1 5 99.3% vs. period 2 5 99.9%; P <.001), and of treatment on heart rate (placebo 5 62.3 vs. active 5 67.1 bpm; P 5.001). Table I reports the results for the ANOVA operating on the slopes of the ME pressure-time function. Those slopes were significantly different among individuals and between treatments. The adjusted average slopes were 6.21 6 2.21 and 4.81 6 2.21 daPa/min for the placebo and PDE treatments. There was no effect of group, ear, or the interaction on this variable. Figure 1 shows a scatterplot of the ME pressuretime slopes for the PDE treatment as a function of the paired slopes for the placebo treatment. The majority of points lay below the identity line for the placebo treatment documenting lesser values for the PDE treatment. As shown in Figure 2 , the ME pressure-time slopes for the right and left ears of individuals were related linearly. The fit of the regression line between right and left slopes was significantly better for the placebo treatment (right slope 5 0.12 3 left slope 1 0.78; r 2 5 0.72) when compared to the PDE treatment (right slope 5 0.71 3 left slope 1 1.76; r 2 5 0.26).
DISCUSSION
For normal auditory function, ME gas pressure needs to be maintained at near ambient levels. However, isolated biological gas pockets, such as the ME, are not stable at ambient pressure, but exhibit either a progressive volume collapse or, if rigid, an exponential pressure decrease to approach the tissue gas pressure of about ambient-600 daPa. 27, 28 The anatomical construction of the ME allows for both of these behaviors, wherein ME pressure first exhibits a progressive decrease to a mucosa-ME hydrostatic pressure gradient of about 2250 daPa, and then the ME gas space shows a volume collapse as vascular fluids accumulate to displace the ME gasvolume. 1 In healthy MEs, this fate is avoided by periodic ET openings, which establish short duration, ME-NP gas-phase communications, and permit gradient-driven ME-NP gas flow that resets ME pressure at near ambient levels. This process represents a homeostatic mechanism to preserve a near-zero ME-ambient pressure-gradient, MEPR, with ET opening being the sole pressure regulator and diffusive ME to blood N 2 transfer being the primary driver of gradient instability. The opposing processes of MEPR operate over different time scales. Specifically, ME volume gas efflux is continuous for relatively long time periods between ET openings (measured in minutes to hours), and ME volume gas influx is a discrete event occurring during a tubal opening (average duration 400 ms). 29 Thus, the V iME g /V eME N2 ratio exhibits a temporal pattern characterized by successive values of one bounding variablelength period during which the ratio decreases. Because ME pressure is governed by the ideal gas law, these changes are reflected as changes in ME pressure, and at stable environmental pressure, changes in the MEambient pressure-gradient. Adequate MEPR requires that the sum of accumulated ME volume gas gain and loss is 0 mL (i.e., V iME g /V eME N2 5 1) at a time, Dt e , within all time-intervals, Dt p , where Dt e is the time between each occurrence of V iME g /V eME N2 5 1, and Dt p is the time required for ME gas volume efflux to drive the MEambient pressure-gradient to the critical level that causes pathology in a specified ME. Thus, MEPR efficiency can be quantified as the Dt p /Dt e time ratio, with higher ratios reflecting greater efficiencies and ratios <1 defining MEPD. Because an individual's risk for conductive hearing loss and certain ME pathologies is inversely related to MEPR efficiency, 30 interventions that effect an increase in the Dt p /Dt e time ratio will decrease those risks and perhaps promote resolution of existing pathologies.
The Dt p /Dt e time ratio can be increased by increasing Dt p , decreasing Dt e , or both. Past approaches to modulating MEPR efficiency focused almost exclusively on decreasing Dt e by pharmacological/surgical interventions intended to improve ET efficiency, but with limited success. 31 Here, the feasibility of the alternative strategy to increase the Dt p /Dt e time ratio was explored. Because Dt p measures the time required for the extant rate of ME volume gas loss to precipitate pathology, it is inversely related to the trans-MEM N 2 exchange rate that in turn depends on the mucosal blood perfusion rate. Consequently, it was hypothesized that pharmacological interventions that decrease the perfusion rate would decrease the trans-MEM N 2 exchange-rate, extend Dt e , and increase the Dt p /Dt e time ratio. That hypothesis was tested using a previously developed 25 and field-tested 26,32 experimental protocol capable of estimating the trans-MEM N 2 exchange-rate from measured values of the trans-MEM N 2 O exchangerate. A formal mathematical description of the blood-ME species exchanges under this protocol documented the correspondence between the measured variable (i.e., slope of the ME pressure-time function) and the parameter to be estimated (i.e., trans-MEM N 2 conductance) as well as the validity of using the surrogate gas, N 2 O, to estimate the trans-MEM N 2 exchange-rate. 1, 25, 26, 32 N 2 O was used as the test gas because it exhibits a perfusionlimited trans-MEM exchange rate that is approximately 33 times faster than the N 2 rate, 33 which allows the required measurements to be made within a reasonable time period. The active treatment, PDE, was chosen for its known mucosal vasoconstrictive effects. 19 Because the trans-MEM N 2 O exchange rate depends on mastoid geometry, 26,32 a cross-over design was used, and the trans-MEM N 2 O exchange rate was compared between placebo and active treatments within ears/persons.
The results support the tested hypothesis that the rate of ME pressure increase in response to a positive trans-MEM blood-ME N 2 O pressure gradient is decreased by treatment with PDE and, by implication, support the validity of the underlying assumptions applicable to this setting. The latter include: 1) oral PDE at the specified dose causes a significant ME mucosal vasoconstriction for a duration sufficient to include the time period when the measurements were made, and 2) this vasoconstriction is expressed as a significant decrease in the ME mucosal blood perfusion rate. Because the trans-MEM exchange rates for both N 2 O and N 2 are governed by the same perfusion-limited exchange equation, it is expected that PDE and other pharmacological modulators of blood perfusion will have predictable effects on the trans-MEM N 2 exchange rate and, consequently, MEPR efficiency. From the effect size for this experiment, it is expected that the dose of PDE used will increase MEPR efficiency by about 33%. Experiments are ongoing in our laboratory to test these expectations.
A few studies reported that ET efficiency was poorer for otherwise healthy MEs with past ME disease when compared to ears without past disease. 34, 35 Extant inflammation with/without ME fluid is associated with an increased trans-MEM inert-gas exchange rate, presumably due to an increased volume-blood perfusion rate for inflamed mucosa. 12, 36, 37 However, the possible effect of disease history on trans-MEM inert-gas exchange rates has not been explored. In this study, persons with and without past ME disease were enrolled, but the analysis identified no significant effect of disease history on the measured trans-MEM N 2 O exchange rate. However, the power to detect expected differences was low given the sample size of 10 subjects/group. Thus, this remains an unresolved question to be evaluated more rigorously in future studies.
As an aside, a significant left-right correlation in the magnitudes of the trans-MEM N 2 O exchange rates was documented. Given the results of previous studies showing rate dependence on mastoid geometry, 26 this correlation may reflect a bilateral symmetry in ME geometry for those enrolled. If supported by future experiments, there may be a basal level of trans-MEM N 2 exchange rate fixed by ME geometry and other factors. In turn, variations in this could affect the degree of achievable pharmacological modulation of the trans-MEM N 2 exchange rate and thereby restrict the expected benefit of using vasoconstrictors as a treatment to improve MEPR efficiency to subgroups pre-selected on the basis of their basal exchange rate.
CONCLUSION
Oral administration of a vasoconstrictive drug decreased the trans-MEM N 2 O exchange-rate. Because all inert-gases are characterized by a perfusion-limited trans-MEM exchange rate, this effect is expected to extend to the trans-MEM N 2 exchange rate, which is the primary determinant of the requisite ET efficiency for adequate MEPR. Modulating ME mucosal bloodperfusion can increase MEPR efficiency but alone cannot stabilize ME pressure at near-ambient levels.
